ホーム > 政策について > 分野別の政策一覧 > 他分野の取り組み > 研究事業 > 平成23年度 厚生労働科学研究費補助金の概要 > 中間・事後評価委員会名簿 > 難病・がん等疾患分野の医療の実用化研究事業(がん関係研究分野) 中間・事後評価委員名簿

難病・がん等疾患分野の医療の実用化研究事業(がん関係研究分野) 中間・事後評価委員名簿

(○:委員長)

 
上田 龍三 愛知医科大学医学部・教授
腫瘍内科学
Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
J Clin Oncol. 2012 Mar 10;30(8):837-42. (Epub 2012 Feb 6)
Nishikawa H, Maeda Y, Ishida T, Gnjatic S, Sato E, Mori F, Sugiyama D, Ito A, Fukumori Y, Utsunomiya A, Inagaki H, Old LJ, Ueda R, Sakaguchi S. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
Blood. 2012 Mar 29;119(13):3097-104. (Epub 2012 Feb 8)
Masaki A, Ishida T, Suzuki S, Ito A, Mori F, Sato F, Narita T, Yamada T, Ri M, Kusumoto S, Komatsu H, Tanaka Y, Niimi A, Inagaki H, Iida S, Ueda R. Autologous Tax-Specific CTL Therapy in a Primary Adult T Cell Leukemia/Lymphoma Cell-Bearing NOD/Shi-scid, IL-2Rγnull Mouse Model
J Immunol. 2013 Jul 1;191(1):135-44. (Epub 2013 Jun 3)
 
大津 敦 国立がん研究センター東病院臨床開発センター長
腫瘍内科
Ohtsu A, Shah M, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first-Line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III Study. J Clin Oncol, 29(30):3968-3976, 2011
Bang YJ, Van Cutsem E, Ohtsu A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010
Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol, 21: 54-59, 2003
 
清木 元治 東京大学・医科学研究所・教授
分子生物学
Targeting the Warburg effect that arises in tumor cells expressing membrane type-1 matrix metalloproteinase. SAKAMOTO T, NIIYA D, and SEIKI M. J. Biol. Chem. 2011 April. 286, 14691-14704
A matrix metalloproteinase expressed on the surface of invasive tumor cells. SATO H, TAKINO T, OKADA Y, CAO J, SHINAGAWA A, YAMAMOTO E, and SEIKI M, Nature. 1994 July; 370, 61-65,
Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. SEIKI M, HATTORI S, HIRAYAMA Y, and YOSHIDA M.
 
中西 洋一 九州大学大学院・教授
臨床腫瘍学・呼吸器内科学・臨床試験
IL1B rs1143634 polymorphism, cigarette smoking, alcohol use, and lung cancer risk in a Japanese population.
Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y.
J Thorac Oncol 5:299-304,2010
Tetracycline-inducible promoter-based conditionally replicative adenoviruses for the control of viral replication.
Zhang H, Takayama K, Zhang L, Uchino J, Harada A, Harada T, Hisasue J, Nakagaki N, Zhou C, Nakanishi Y.
Cancer Gene Ther 16:415-422,2009
A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer.
N Ebi, H Semba, S Tokunaga, K Takayama, H Wataya, T Kuraki, H Yamamoto, S Akamine, I Okamoto, Y Nakanishi. (Lung Oncology Group in Kyushu Japan)
J Thorac Oncol 10:1166-1171, 2008
 
野田 哲生 財団法人癌研究会有明病院 研究所長
福岡 正博 和泉市立病院がんセンター長・特別顧問
臨床腫瘍学
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. J Clin Oncol 29(21): 2866-74, 2011.
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. N Engl J Med. 361(10): 947-57, 2009.
Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M and Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst.83(12): 855-61, 1991.
 
森山 紀之 国立がん研究センター がん予防・検診研究センター長
画像診断
Detection Failures in Spiral CT Screening for Lung Cancer: Analysis CT Findings. N. Moriyama. Ragiology. 1999; 212(1):61-66.

Development of Helical CT and Assessment of Its Clinical Value. N. Moriyama. Medical Review. 1994; 49:579-581.
「肝CT読影の実際」森山紀之 金原出版 (1986).

ホーム > 政策について > 分野別の政策一覧 > 他分野の取り組み > 研究事業 > 平成23年度 厚生労働科学研究費補助金の概要 > 中間・事後評価委員会名簿 > 難病・がん等疾患分野の医療の実用化研究事業(がん関係研究分野) 中間・事後評価委員名簿

ページの先頭へ戻る